Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced the commencement of a pre-marketing clinical study for its polyvinyl alcohol embolic microspheres. The company has completed the first pre-marketing clinical implantation in transcatheter arterial chemoembolization (TACE) surgery for left lobe lesions in patients with primary liver cancer.
The product comes in two models: yellow and colorless. The yellow model is designed to be radiopaque under X-rays, enhancing its visibility during procedures. The colorless model boasts excellent vascular compatibility. The yellow type features a minimum particle size specification of 40-90 μm, allowing for rapid drug loading and effective embolization at the ends of tumor blood vessels, leading to more thorough tumor necrosis. Its persistent imaging function aids in determining the endpoint of embolization during surgery, reducing the risk of reflux and providing visual guidance for postoperative follow-up and treatment.- Flcube.com
